30th International Symposium on ALS/MND - Perth, Australia - Abstract Book
27-11-2019
- C2 The biomarker challenge - NEDERLANDS
- C3 The fine balance of proteostasis and its implications - NEDERLANDS
- C8 The ALS platform trial - NEDERLANDS
- C20 Modeling ALS - NEDERLANDS
- C26 How frequent are pauses in ALS - NEDERLANDS
- C27 Future directions in ALS genomics - NEDERLANDS
- C32 Designer DNA drug therapy - NEDERLANDS
- C34 An AI drug discovery & C35 Machine learning - NEDERLANDS
- C36 Relevance of CuATSM to sporadic ALS - NEDERLANDS
- C37 Pseudobulbar affect in ALS - NEDERLANDS
- C52 Supporting family carers from diagnosis to bereavemen - NEDERLANDS
- C53 Research and support for young caregivers - NEDERLANDS
- C55 Individual quality of life - NEDERLANDS
- C65 Palliative care and healthcare utilization - NEDERLANDS
- C81 Telehealth provides meaningful contributions to patient care - NEDERLANDS
- C93 Antioxidant drugs reveal the potential for patient stratification - NEDERLANDS
- C94 Intrathecal AAV9-SOD1-shRNA administration - NEDERLANDS
- C95 Loss of appetite is associated with a loss of weight - NEDERLANDS
- C110 The dawn of brain computer interfaces - NEDERLANDS
